160 related articles for article (PubMed ID: 10337009)
1. Induction in transgenic mice of HLA-A2.1-restricted cytotoxic T cells specific for a peptide sequence from a mutated p21ras protein.
Escobar P; Yu Z; Terskikh A; Holmes N; Corradin G; Mach JP; Healy F
Clin Exp Immunol; 1999 May; 116(2):214-9. PubMed ID: 10337009
[TBL] [Abstract][Full Text] [Related]
2. Identification of a human CD8+ T lymphocyte neo-epitope created by a ras codon 12 mutation which is restricted by the HLA-A2 allele.
Bergmann-Leitner ES; Kantor JA; Shupert WL; Schlom J; Abrams SI
Cell Immunol; 1998 Aug; 187(2):103-16. PubMed ID: 9732698
[TBL] [Abstract][Full Text] [Related]
3. Induction and characterization of cytotoxic T-lymphocytes recognizing a mutated p21ras peptide presented by HLA-A*0201.
Van Elsas A; Nijman HW; Van der Minne CE; Mourer JS; Kast WM; Melief CJ; Schrier PI
Int J Cancer; 1995 May; 61(3):389-96. PubMed ID: 7729952
[TBL] [Abstract][Full Text] [Related]
4. Generation of stable CD4+ and CD8+ T cell lines from patients immunized with ras oncogene-derived peptides reflecting codon 12 mutations.
Abrams SI; Khleif SN; Bergmann-Leitner ES; Kantor JA; Chung Y; Hamilton JM; Schlom J
Cell Immunol; 1997 Dec; 182(2):137-51. PubMed ID: 9514698
[TBL] [Abstract][Full Text] [Related]
5. A single amino acid substitution in HLA-A2 can alter the selection of the cytotoxic T lymphocyte repertoire that responds to influenza virus matrix peptide 55-73.
Shimojo N; Cowan EP; Engelhard VH; Maloy WL; Coligan JE; Biddison WE
J Immunol; 1989 Jul; 143(2):558-64. PubMed ID: 2472444
[TBL] [Abstract][Full Text] [Related]
6. A panel of unique HLA-A2 mutant molecules define epitopes recognized by HLA-A2-specific antibodies and cytotoxic T lymphocytes.
Hogan KT; Clayberger C; Bernhard EJ; Walk SF; Ridge JP; Parham P; Krensky AM; Engelhard VH
J Immunol; 1989 Mar; 142(6):2097-104. PubMed ID: 2466083
[TBL] [Abstract][Full Text] [Related]
7. Influenza A-specific, HLA-A2.1-restricted cytotoxic T lymphocytes from HLA-A2.1 transgenic mice recognize fragments of the M1 protein.
Engelhard VH; Lacy E; Ridge JP
J Immunol; 1991 Feb; 146(4):1226-32. PubMed ID: 1704033
[TBL] [Abstract][Full Text] [Related]
8. T-cell immunity to oncogenic proteins including mutated ras and chimeric bcr-abl.
Cheever MA; Chen W; Disis ML; Takahashi M; Peace DJ
Ann N Y Acad Sci; 1993 Aug; 690():101-12. PubMed ID: 8103658
[TBL] [Abstract][Full Text] [Related]
9. Identification of overlapping epitopes in mutant ras oncogene peptides that activate CD4+ and CD8+ T cell responses.
Abrams SI; Stanziale SF; Lunin SD; Zaremba S; Schlom J
Eur J Immunol; 1996 Feb; 26(2):435-43. PubMed ID: 8617315
[TBL] [Abstract][Full Text] [Related]
10. Memory T cells of a patient with follicular thyroid carcinoma recognize peptides derived from mutated p21 ras (Gln-->Leu61).
Gedde-Dahl T; Spurkland A; Eriksen JA; Thorsby E; Gaudernack G
Int Immunol; 1992 Nov; 4(11):1331-7. PubMed ID: 1282032
[TBL] [Abstract][Full Text] [Related]
11. Lysis of ras oncogene-transformed cells by specific cytotoxic T lymphocytes elicited by primary in vitro immunization with mutated ras peptide.
Peace DJ; Smith JW; Chen W; You SG; Cosand WL; Blake J; Cheever MA
J Exp Med; 1994 Feb; 179(2):473-9. PubMed ID: 8294861
[TBL] [Abstract][Full Text] [Related]
12. Novel breast-tumor-associated MUC1-derived peptides: characterization in Db-/- x beta2 microglobulin (beta2m) null mice transgenic for a chimeric HLA-A2.1/Db-beta2 microglobulin single chain.
Carmon L; El-Shami KM; Paz A; Pascolo S; Tzehoval E; Tirosh B; Koren R; Feldman M; Fridkin M; Lemonnier FA; Eisenbach L
Int J Cancer; 2000 Feb; 85(3):391-7. PubMed ID: 10652432
[TBL] [Abstract][Full Text] [Related]
13. Cytotoxic T-lymphocyte responses against mutated p21 ras peptides: an analysis of specific T-cell-receptor gene usage.
Juretic A; Jürgens-Göbel J; Schaefer C; Noppen C; Willimann TE; Kocher T; Zuber M; Harder F; Heberer M; Spagnoli GC
Int J Cancer; 1996 Nov; 68(4):471-8. PubMed ID: 8945618
[TBL] [Abstract][Full Text] [Related]
14. T cell recognition of transforming proteins encoded by mutated ras proto-oncogenes.
Peace DJ; Chen W; Nelson H; Cheever MA
J Immunol; 1991 Mar; 146(6):2059-65. PubMed ID: 2005390
[TBL] [Abstract][Full Text] [Related]
15. Amino acid substitutions at position 97 in HLA-A2 segregate cytolysis from cytokine release in MART-1/Melan-A peptide AAGIGILTV-specific cytotoxic T lymphocytes.
Maeurer MJ; Chan HW; Karbach J; Salter RD; Knuth A; Lotze MT; Storkus WJ
Eur J Immunol; 1996 Nov; 26(11):2613-23. PubMed ID: 8921947
[TBL] [Abstract][Full Text] [Related]
16. The kinetics of peptide binding to HLA-A2 and the conformation of the peptide-A2 complex can be determined by amino acid side chains on the floor of the peptide binding groove.
Shimojo N; Anderson RW; Mattson DH; Turner RV; Coligan JE; Biddison WE
Int Immunol; 1990; 2(3):193-200. PubMed ID: 2088485
[TBL] [Abstract][Full Text] [Related]
17. Unconventional cytotoxic T lymphocyte recognition of synthetic peptides corresponding to residues 1-23 of Ras protein.
Yin L; Thomas C; Hsuan JJ; Stauss HJ
Eur J Immunol; 1994 Sep; 24(9):1988-92. PubMed ID: 8088318
[TBL] [Abstract][Full Text] [Related]
18. Identification of an enhancer agonist cytotoxic T lymphocyte peptide from human carcinoembryonic antigen.
Zaremba S; Barzaga E; Zhu M; Soares N; Tsang KY; Schlom J
Cancer Res; 1997 Oct; 57(20):4570-7. PubMed ID: 9377571
[TBL] [Abstract][Full Text] [Related]
19. Induction of human cytotoxic T lymphocytes that preferentially recognise tumour cells bearing a conformational p53 mutant.
McArdle SE; Rees RC; Mulcahy KA; Saba J; McIntyre CA; Murray AK
Cancer Immunol Immunother; 2000 Oct; 49(8):417-25. PubMed ID: 11043848
[TBL] [Abstract][Full Text] [Related]
20. Molecular analysis of presentation by HLA-A2.1 of a promiscuously binding V3 loop peptide from the HIV-envelope protein to human cytotoxic T lymphocytes.
Alexander-Miller MA; Parker KC; Tsukui T; Pendleton CD; Coligan JE; Berzofsky JA
Int Immunol; 1996 May; 8(5):641-9. PubMed ID: 8671651
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
